Kuros Biosciences Ag Stock Performance
| CSBTF Stock | USD 21.40 3.90 15.42% |
The company secures a Beta (Market Risk) of -0.76, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Kuros Biosciences are expected to decrease at a much lower rate. During the bear market, Kuros Biosciences is likely to outperform the market. At this point, Kuros Biosciences has a negative expected return of -0.34%. Please make sure to verify Kuros Biosciences' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Kuros Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kuros Biosciences AG has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 28.4 M | |
| Total Cashflows From Investing Activities | -374 K | |
| Free Cash Flow | -5.8 M |
Kuros |
Kuros Biosciences Relative Risk vs. Return Landscape
If you would invest 2,900 in Kuros Biosciences AG on October 26, 2024 and sell it today you would lose (760.00) from holding Kuros Biosciences AG or give up 26.21% of portfolio value over 90 days. Kuros Biosciences AG is currently producing negative expected returns and takes up 5.3719% volatility of returns over 90 trading days. Put another way, 47% of traded pink sheets are less volatile than Kuros, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Kuros Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kuros Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Kuros Biosciences AG, and traders can use it to determine the average amount a Kuros Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0627
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CSBTF |
Estimated Market Risk
| 5.37 actual daily | 47 53% of assets are more volatile |
Expected Return
| -0.34 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kuros Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kuros Biosciences by adding Kuros Biosciences to a well-diversified portfolio.
Kuros Biosciences Fundamentals Growth
Kuros Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Kuros Biosciences, and Kuros Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kuros Pink Sheet performance.
| Return On Equity | -0.14 | |||
| Return On Asset | -0.0667 | |||
| Profit Margin | (0.74) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 40.53 M | |||
| Shares Outstanding | 36.54 M | |||
| Price To Earning | 0.33 X | |||
| Price To Book | 0.79 X | |||
| Price To Sales | 4.63 X | |||
| Revenue | 13.81 M | |||
| EBITDA | (5.29 M) | |||
| Cash And Equivalents | 28.62 M | |||
| Cash Per Share | 0.87 X | |||
| Total Debt | 2.21 M | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 2.23 X | |||
| Cash Flow From Operations | (5.45 M) | |||
| Earnings Per Share | (0.24) X | |||
| Total Asset | 91.34 M | |||
| Retained Earnings | (37 M) | |||
| Current Asset | 18 M | |||
| Current Liabilities | 2 M | |||
About Kuros Biosciences Performance
By analyzing Kuros Biosciences' fundamental ratios, stakeholders can gain valuable insights into Kuros Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kuros Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kuros Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. KUROS BIOSCIENCES operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 58 people.Things to note about Kuros Biosciences performance evaluation
Checking the ongoing alerts about Kuros Biosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Kuros Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kuros Biosciences generated a negative expected return over the last 90 days | |
| Kuros Biosciences has high historical volatility and very poor performance | |
| The company reported the revenue of 13.81 M. Net Loss for the year was (7.54 M) with profit before overhead, payroll, taxes, and interest of 10.07 M. | |
| Kuros Biosciences AG has accumulated about 28.62 M in cash with (5.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87. | |
| Roughly 35.0% of the company shares are held by company insiders |
- Analyzing Kuros Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kuros Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Kuros Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kuros Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kuros Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kuros Biosciences' pink sheet. These opinions can provide insight into Kuros Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Kuros Pink Sheet analysis
When running Kuros Biosciences' price analysis, check to measure Kuros Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kuros Biosciences is operating at the current time. Most of Kuros Biosciences' value examination focuses on studying past and present price action to predict the probability of Kuros Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kuros Biosciences' price. Additionally, you may evaluate how the addition of Kuros Biosciences to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |